Paper Details

  1. Home
  2. Paper Details

Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.

Author: JohannsenAntje, Röwert-HuberJoachim, SterryWolfram, StockflethEggert, UlrichClaas, UlrichMartina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy and safety of diclofenac gel for treating actinic keratosis (AK) in organ transplant recipients (OTRs). Diclofenac gel resulted in a 41% complete clearance rate of AK lesions compared to 0% in the vehicle group. While 55% of patients experienced recurrent AK, no patient developed invasive squamous cell carcinoma (SCC) within 24 months of follow-up.
Paper Details　
Original Abstract of the Article :
Increasing incidence rates of cutaneous malignancies, paralleling rising survival times of grafts and patients in organ transplant recipients, represents an escalating challenge for dermatologists worldwide. Especially, invasive squamous cell carcinomas (SCC) in immuno-compromised patients are chara...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1684/ejd.2010.1010

データ提供：米国国立医学図書館（NLM）

Diclofenac Gel: A Promising Treatment for Actinic Keratoses

This study delves into the realm of dermatology, focusing on the treatment of actinic keratoses (AK), precancerous skin lesions common in organ transplant recipients. The research investigates the safety and efficacy of topical diclofenac 3% gel in treating AK in this high-risk population. The study found that diclofenac gel was significantly more effective than placebo in clearing AK lesions and was well-tolerated, with minimal side effects. While the study also observed a recurrence of AK lesions after treatment, it did not find any instances of invasive squamous cell carcinoma in the treated areas.

A Step Forward in Managing Skin Cancer Risk

The study's findings offer a promising treatment option for managing AK in organ transplant recipients. Diclofenac gel, with its demonstrated efficacy and safety profile, provides a valuable tool for reducing the risk of developing invasive squamous cell carcinoma. The study's focus on this high-risk population is particularly important, given the increased incidence of skin cancers in immunocompromised individuals.

Protecting Your Skin

This study underscores the importance of vigilant skin care, especially for individuals who are immunocompromised or at increased risk for skin cancer. Regular skin examinations and early intervention for any suspicious lesions are crucial for maintaining skin health. The study's findings offer hope for effective treatment options for AK, helping to prevent the development of more serious skin cancers.

Dr. Camel's Conclusion

Imagine a camel traversing a harsh desert, its skin exposed to the sun's damaging rays. Actinic keratoses are like these sun-induced blemishes on the skin. This research offers a valuable remedy, showcasing the efficacy and safety of diclofenac gel in treating these precancerous lesions, protecting the skin from further damage.
Date :
  1. Date Completed 2010-09-29
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

20507841

DOI: Digital Object Identifier

10.1684/ejd.2010.1010

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.